Conditional okay for cannabis prescription drug

Sibbald, Barbara
June 2005
CMAJ: Canadian Medical Association Journal;6/21/2005, Vol. 172 Issue 13, p1672
Academic Journal
Reports on a conditional approval issued by Health Canada on the first cannabis-derived prescription pain killer, Sativex, as of June 2005. Reason of Health Canada for issuing the conditional approval; Effect of Sativex on patients with multiple sclerosis; Way of controlling the adverse effects of Sativex.


Related Articles

  • Safety of drugs is threatened by looser approval process. Schafer, Arthur // CCPA Monitor;Mar2011, Vol. 17 Issue 9, p29 

    The article focuses on the looser drug approval process that threatened drugs safety in Canada. It remarks on the drug approval process and stage-managed technical consultations of Health Canada in which new drugs would be presumed to be safe unless critics can prove they will be more harmful...

  • Baclofen.  // Reactions Weekly;5/14/2011, Issue 1351, p13 

    The article describes the case of a 41-year-old woman with multiple sclerosis, who experienced an epileptic seizure following treatment with intrathecal baclofen.

  • Fampridine May Improve Walking and Quality of Life in Patients With MS.  // Neurology Reviews;Nov2015, Vol. 23 Issue 11, p46 

    The article reports that according to a research, prolonged-release fampridine improves walking and quality of life in patients with multiple sclerosis (MS) and states that side effects of trials of fampridine included insomnia, urinary tract infections, dizziness and headaches.

  • Health Canada issues reminder of benzocaine risks.  // Reactions Weekly;5/7/2011, Issue 1350, p3 

    This article reports on the move of Health Canada to remind the people of the risks associated with the use of topical benzocaine.

  • Report adverse reactions to Health Canada.  // British Columbia Medical Journal;Jun2013, Vol. 55 Issue 5, p233 

    The article announces that Health Canada is asking people to report a serious or unexpected adverse reaction because of any health product.

  • Growing support for the Canada Vigilance Program.  // Reactions Weekly;5/1/2010, Issue 1299, p3 

    The article deals with the 35% increase in the number of domestic reports of suspected adverse drug reactions submitted to Health Canada from 2008 to 2009.

  • Health Canada is advising consumers not to use Neophase Formula for Men.  // Reactions Weekly;8/12/2006, Issue 1114, p2 

    The article reports on the advise by Health Canada for consumers not to use Neophase Formula for Men from Vigor Nutriceutical Healthcare Inc., because it contained a modified version of sildenafil which can lead to serious health risks.

  • Health Canada update 2010.  // Reactions Weekly;7/23/2011, Issue 1361, p4 

    The article reports that 32,921 domestic adverse reaction cases were disclosed to Health Canada in 2010, with most of the cases involving reactions with pharmaceuticals and biotechnology products.

  • Febuxostat associated with DRESS syndrome?  // Reactions Weekly;Jun2015, Vol. 1555 Issue 1, p2 

    The article reports that Health Canada's safety review on the drug febuxostat (Uloric) and its association with agranulocytosis or DRESS syndrome.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics